home.social

#genetherapy — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #genetherapy, aggregated by home.social.

  1. Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

    The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

    #news #health #medicine #cholesterol #GeneTherapy #GeneEditing

  2. Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

    The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

    #news #health #medicine #cholesterol #GeneTherapy #GeneEditing

  3. Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

    The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

    #news #health #medicine #cholesterol #GeneTherapy #GeneEditing

  4. Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

    The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

    #news #health #medicine #cholesterol #GeneTherapy #GeneEditing

  5. Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

    The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

    #news #health #medicine #cholesterol #GeneTherapy #GeneEditing

  6. One infusion. One time. Possibly forever. A breakthrough gene-editing treatment just slashed LDL "bad" cholesterol by up to 62% — and the results are holding 18 months later. Published in the New England Journal of Medicine, the small study of 35 patients could reshape how we fight heart disease, which kills 800,000 Americans annually. No daily pills. No repeat treatments. Just one shot. Experts call it potentially "game-changing." Larger trials are next — but the early signs are extraordinary. The future of heart health may have just arrived. #HeartDisease #GeneTherapy #MedicalBreakthrough #Cholesterol #Health #Science #Medicine #NEJM #Innovation #Healthcare nytimes.com/2026/05/25/health/

  7. One infusion. One time. Possibly forever. A breakthrough gene-editing treatment just slashed LDL "bad" cholesterol by up to 62% — and the results are holding 18 months later. Published in the New England Journal of Medicine, the small study of 35 patients could reshape how we fight heart disease, which kills 800,000 Americans annually. No daily pills. No repeat treatments. Just one shot. Experts call it potentially "game-changing." Larger trials are next — but the early signs are extraordinary. The future of heart health may have just arrived. #HeartDisease #GeneTherapy #MedicalBreakthrough #Cholesterol #Health #Science #Medicine #NEJM #Innovation #Healthcare nytimes.com/2026/05/25/health/

  8. One infusion. One time. Possibly forever. A breakthrough gene-editing treatment just slashed LDL "bad" cholesterol by up to 62% — and the results are holding 18 months later. Published in the New England Journal of Medicine, the small study of 35 patients could reshape how we fight heart disease, which kills 800,000 Americans annually. No daily pills. No repeat treatments. Just one shot. Experts call it potentially "game-changing." Larger trials are next — but the early signs are extraordinary. The future of heart health may have just arrived. #HeartDisease #GeneTherapy #MedicalBreakthrough #Cholesterol #Health #Science #Medicine #NEJM #Innovation #Healthcare nytimes.com/2026/05/25/health/

  9. One infusion. One time. Possibly forever. A breakthrough gene-editing treatment just slashed LDL "bad" cholesterol by up to 62% — and the results are holding 18 months later. Published in the New England Journal of Medicine, the small study of 35 patients could reshape how we fight heart disease, which kills 800,000 Americans annually. No daily pills. No repeat treatments. Just one shot. Experts call it potentially "game-changing." Larger trials are next — but the early signs are extraordinary. The future of heart health may have just arrived. #HeartDisease #GeneTherapy #MedicalBreakthrough #Cholesterol #Health #Science #Medicine #NEJM #Innovation #Healthcare nytimes.com/2026/05/25/health/

  10. One infusion. One time. Possibly forever. A breakthrough gene-editing treatment just slashed LDL "bad" cholesterol by up to 62% — and the results are holding 18 months later. Published in the New England Journal of Medicine, the small study of 35 patients could reshape how we fight heart disease, which kills 800,000 Americans annually. No daily pills. No repeat treatments. Just one shot. Experts call it potentially "game-changing." Larger trials are next — but the early signs are extraordinary. The future of heart health may have just arrived. #HeartDisease #GeneTherapy #MedicalBreakthrough #Cholesterol #Health #Science #Medicine #NEJM #Innovation #Healthcare nytimes.com/2026/05/25/health/

  11. Adenine base editing, a highly targeted form of genetic medicine, has been successfully deployed in a preclinical mouse model to correct the specific DNA mutation (SCN1A) responsible for Dravet syndrome, a severe and often fatal form of childhood epilepsy.
    #MolecularGenetics #Neurobiology #GeneTherapy #PrecisionMedicine #sflorg
    sflorg.com/2026/05/gen05142601

  12. Adenine base editing, a highly targeted form of genetic medicine, has been successfully deployed in a preclinical mouse model to correct the specific DNA mutation (SCN1A) responsible for Dravet syndrome, a severe and often fatal form of childhood epilepsy.
    #MolecularGenetics #Neurobiology #GeneTherapy #PrecisionMedicine #sflorg
    sflorg.com/2026/05/gen05142601

  13. Adenine base editing, a highly targeted form of genetic medicine, has been successfully deployed in a preclinical mouse model to correct the specific DNA mutation (SCN1A) responsible for Dravet syndrome, a severe and often fatal form of childhood epilepsy.
    #MolecularGenetics #Neurobiology #GeneTherapy #PrecisionMedicine #sflorg
    sflorg.com/2026/05/gen05142601

  14. Adenine base editing, a highly targeted form of genetic medicine, has been successfully deployed in a preclinical mouse model to correct the specific DNA mutation (SCN1A) responsible for Dravet syndrome, a severe and often fatal form of childhood epilepsy.
    #MolecularGenetics #Neurobiology #GeneTherapy #PrecisionMedicine #sflorg
    sflorg.com/2026/05/gen05142601

  15. Adenine base editing, a highly targeted form of genetic medicine, has been successfully deployed in a preclinical mouse model to correct the specific DNA mutation (SCN1A) responsible for Dravet syndrome, a severe and often fatal form of childhood epilepsy.
    #MolecularGenetics #Neurobiology #GeneTherapy #PrecisionMedicine #sflorg
    sflorg.com/2026/05/gen05142601

  16. First Clinical Trial for a GLP-1 Gene Therapy Greenlit in Europe

    Credit: Tingting Ji / iStock / Getty Images Plus Fractyl Health has received regulatory approval in the Netherlands…
    #Europe #EU #clinicaltrial #diabetes #genetherapy(therapeutics) #news&features #pancreas #topics #translationalresearch
    europesays.com/europe/40252/

  17. Researchers Identify Key Genes for Limb Regeneration in Animals

    📰 Original title: Scientists found the "holy grail" gene that could one day help humans regrow limbs

    🤖 IA: It's clickbait ⚠️
    👥 Users: It's clickbait ⚠️

    View full AI summary: killbait.com/en/researchers-id

    #genetics #genetherapy #regeneration #limbgrowth

  18. Researchers Identify Key Genes for Limb Regeneration in Animals

    📰 Original title: Scientists found the "holy grail" gene that could one day help humans regrow limbs

    🤖 IA: It's clickbait ⚠️
    👥 Users: It's clickbait ⚠️

    View full AI summary: killbait.com/en/researchers-id

    #genetics #genetherapy #regeneration #limbgrowth

  19. Researchers Identify Key Genes for Limb Regeneration in Animals

    📰 Original title: Scientists found the "holy grail" gene that could one day help humans regrow limbs

    🤖 IA: It's clickbait ⚠️
    👥 Users: It's clickbait ⚠️

    View full AI summary: killbait.com/en/researchers-id

    #genetics #genetherapy #regeneration #limbgrowth

  20. Researchers Identify Key Genes for Limb Regeneration in Animals

    📰 Original title: Scientists found the "holy grail" gene that could one day help humans regrow limbs

    🤖 IA: It's clickbait ⚠️
    👥 Users: It's clickbait ⚠️

    View full AI summary: killbait.com/en/researchers-id

    #genetics #genetherapy #regeneration #limbgrowth

  21. 🧠 Could the brain reveal vision loss more accurately than traditional eye tests?

    🔗 Using Steady-State Visual Evoked Potentials to Characterize Wide-Ranging Retinopathy Linked to CRB1: Implications for Clinical Trials. Computational and Structural Biotechnology Journal (CSBJ). DOI: doi.org/10.34133/csbj.0042

    📚 CSBJ - A Science Partner Journal: spj.science.org/journal/csbj

    #Neuroscience #Ophthalmology #RetinalDiseases #GeneTherapy #EEG #BrainResearch #DigitalHealth #PrecisionMedicine #Neuroimaging

  22. 🧠 Could the brain reveal vision loss more accurately than traditional eye tests?

    🔗 Using Steady-State Visual Evoked Potentials to Characterize Wide-Ranging Retinopathy Linked to CRB1: Implications for Clinical Trials. Computational and Structural Biotechnology Journal (CSBJ). DOI: doi.org/10.34133/csbj.0042

    📚 CSBJ - A Science Partner Journal: spj.science.org/journal/csbj

    #Neuroscience #Ophthalmology #RetinalDiseases #GeneTherapy #EEG #BrainResearch #DigitalHealth #PrecisionMedicine #Neuroimaging

  23. 🧠 Could the brain reveal vision loss more accurately than traditional eye tests?

    🔗 Using Steady-State Visual Evoked Potentials to Characterize Wide-Ranging Retinopathy Linked to CRB1: Implications for Clinical Trials. Computational and Structural Biotechnology Journal (CSBJ). DOI: doi.org/10.34133/csbj.0042

    📚 CSBJ - A Science Partner Journal: spj.science.org/journal/csbj

    #Neuroscience #Ophthalmology #RetinalDiseases #GeneTherapy #EEG #BrainResearch #DigitalHealth #PrecisionMedicine #Neuroimaging

  24. 🧠 Could the brain reveal vision loss more accurately than traditional eye tests?

    🔗 Using Steady-State Visual Evoked Potentials to Characterize Wide-Ranging Retinopathy Linked to CRB1: Implications for Clinical Trials. Computational and Structural Biotechnology Journal (CSBJ). DOI: doi.org/10.34133/csbj.0042

    📚 CSBJ - A Science Partner Journal: spj.science.org/journal/csbj

    #Neuroscience #Ophthalmology #RetinalDiseases #GeneTherapy #EEG #BrainResearch #DigitalHealth #PrecisionMedicine #Neuroimaging

  25. 🧠 Could the brain reveal vision loss more accurately than traditional eye tests?

    🔗 Using Steady-State Visual Evoked Potentials to Characterize Wide-Ranging Retinopathy Linked to CRB1: Implications for Clinical Trials. Computational and Structural Biotechnology Journal (CSBJ). DOI: doi.org/10.34133/csbj.0042

    📚 CSBJ - A Science Partner Journal: spj.science.org/journal/csbj

    #Neuroscience #Ophthalmology #RetinalDiseases #GeneTherapy #EEG #BrainResearch #DigitalHealth #PrecisionMedicine #Neuroimaging

  26. 👂🧬 The #FDA approved #Otarmeni, the first gene therapy designed to restore #hearing in individuals with a rare form of genetic #deafness caused by OTOF gene mutations.

    The one-time treatment delivers a functional copy of the gene into the inner ear, enabling cells to transmit #sound signals to the #brain.

    👉 livescience.com/health/genetic

    #genetics #health #science #biology #medicine #biotechnology #research #genetherapy #innovation

  27. 👂🧬 The #FDA approved #Otarmeni, the first gene therapy designed to restore #hearing in individuals with a rare form of genetic #deafness caused by OTOF gene mutations.

    The one-time treatment delivers a functional copy of the gene into the inner ear, enabling cells to transmit #sound signals to the #brain.

    👉 livescience.com/health/genetic

    #genetics #health #science #biology #medicine #biotechnology #research #genetherapy #innovation

  28. 👂🧬 The #FDA approved #Otarmeni, the first gene therapy designed to restore #hearing in individuals with a rare form of genetic #deafness caused by OTOF gene mutations.

    The one-time treatment delivers a functional copy of the gene into the inner ear, enabling cells to transmit #sound signals to the #brain.

    👉 livescience.com/health/genetic

    #genetics #health #science #biology #medicine #biotechnology #research #genetherapy #innovation

  29. 👂🧬 The #FDA approved #Otarmeni, the first gene therapy designed to restore #hearing in individuals with a rare form of genetic #deafness caused by OTOF gene mutations.

    The one-time treatment delivers a functional copy of the gene into the inner ear, enabling cells to transmit #sound signals to the #brain.

    👉 livescience.com/health/genetic

    #genetics #health #science #biology #medicine #biotechnology #research #genetherapy #innovation

  30. 👂🧬 The #FDA approved #Otarmeni, the first gene therapy designed to restore #hearing in individuals with a rare form of genetic #deafness caused by OTOF gene mutations.

    The one-time treatment delivers a functional copy of the gene into the inner ear, enabling cells to transmit #sound signals to the #brain.

    👉 livescience.com/health/genetic

    #genetics #health #science #biology #medicine #biotechnology #research #genetherapy #innovation

  31. Gene therapy helps restore vision in six-year-old girl with rare genetic condition

    📰 Original title: Six-year-old girl has sight restored by first-of-a-kind gene therapy

    🤖 IA: It's not clickbait ✅
    👥 Usuarios: It's not clickbait ✅

    View full AI summary: killbait.com/en/gene-therapy-h

    #genetics #genetherapy

  32. Six-Year-Old's Vision Altered by Gene Intervention

    Six-year-old Saffie Sandford from Stevenage sees better after Luxturna gene therapy for Leber's Congenital Amaurosis at Great Ormond Street Hospital.

    #GeneTherapy, #Luxturna, #LCA, #Stevenage, #EyeHealth

    newsletter.tf/stevenage-girl-v

  33. A six-year-old girl's vision has improved significantly after a one-off gene therapy treatment. This is the first time this therapy has been used on such a young child for this condition.

    #GeneTherapy, #Luxturna, #LCA, #Stevenage, #EyeHealth
    newsletter.tf/stevenage-girl-v

  34. Common gene in axolotls, mice and zebrafish may unlock human limb regrowth

    Investigating a common gene in three very different species – axolotls, mice and zebrafish – scientists have discovered…
    #NewsBeep #News #Health #Amputations #AU #Australia #Bone #Brain #Cancer #diabetes #Epidermis #Gene #genetherapy #Genes #Genetic #Heart #research #Skin #therapy #Vascular
    newsbeep.com/au/622119/

  35. Common gene in axolotls, mice and zebrafish may unlock human limb regrowth

    Investigating a common gene in three very different species – axolotls, mice and zebrafish – scientists have discovered…
    #NewsBeep #News #Health #Amputations #AU #Australia #Bone #Brain #Cancer #diabetes #Epidermis #Gene #genetherapy #Genes #Genetic #Heart #research #Skin #therapy #Vascular
    newsbeep.com/au/622119/